Status:
COMPLETED
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
Lead Sponsor:
Alza Corporation, DE, USA
Conditions:
Chronic Small Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
Detailed Description
Trials with a new, first-in-class drug will be done to ascertain safety, tolerability, absorption and other effects in the treatment of psoriasis, such as effects on biomarkers. Approximately 60 adult...
Eligibility Criteria
Inclusion
- Diagnosis of plaque psoriasis for at least 6 months
- willingness to undergo tissue biopsies
Exclusion
- No current oral or injectable medications for psoriasis (30 days to 3 months)
- no other major health issues
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00396422
Start Date
September 1 2006
End Date
March 1 2007
Last Update
February 18 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.